2022
Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma
Avery J, Chandhok N, Rainey C, Torres R, Huntington S, Isufi I, Seropian S, Xu ML, Foss F. Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2022, 22: 680-689. PMID: 35568635, DOI: 10.1016/j.clml.2022.04.019.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaBone marrow involvementBlood involvementFlow cytometryMarrow involvementNodal subtypesAggressive peripheral T-cell lymphomaNodal T-cell lymphomasNegative flow cytometryPeripheral blood involvementPositive flow cytometryMalignant T cellsMalignant tumor cellsMedian PFSTime ofdiagnosisOverall survivalLymph nodesPoor outcomeDisease stagePeripheral bloodT cellsPrognostic measuresRare subgroupLymphoma
2021
New nonchemotherapy treatment options for cutaneous T-cell lymphomas
Xu S, Foss F. New nonchemotherapy treatment options for cutaneous T-cell lymphomas. Expert Review Of Anticancer Therapy 2021, 21: 1017-1028. PMID: 33554707, DOI: 10.1080/14737140.2021.1882859.Peer-Reviewed Original ResearchConceptsMF/Sézary syndromeSézary syndromeMycosis fungoidesTreatment optionsNovel agentsCutaneous T-cell lymphomaCAR T-cell therapyAdditional novel agentsT-cell lymphomaT-cell therapyAntibody-based therapiesHistone deacetylase inhibitorsConventional chemotherapy approachesCheckpoint inhibitorsImmunomodulatory treatmentBrentuximab vedotinSystemic therapyAntibody agentsComplete responseLymph nodesTreatment armamentariumT cellsChemotherapy approachesImmune effectorsSmall molecule inhibitors
2019
DUSP22-IRF4 rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma
Wang M, Kibbi N, Ring N, Siddon A, Foss F, Totonchy M. DUSP22-IRF4 rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma. BMJ Case Reports 2019, 12: e230641. PMID: 31570354, PMCID: PMC6768350, DOI: 10.1136/bcr-2019-230641.Peer-Reviewed Original ResearchConceptsAnaplastic large cell lymphomaPrimary systemic anaplastic large cell lymphomaSystemic anaplastic large cell lymphomaLarge cell lymphomaPoor prognosisSubcutaneous nodulesCell lymphomaGenetic testingALK-negative anaplastic large cell lymphomaBrentuximab vedotin monotherapySetting of HIVHIV-negative patientsCases of AIDSAnaplastic lymphoma kinaseHIV/AIDSComplete remissionDiffuse lymphadenopathyDisease courseFavorable prognosisLymph nodesAggressive lymphomaLymphoproliferative disordersLymphoma kinaseLymphomaAIDS
2018
BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition
Kim R, Lewis JM, Cyrenne BM, Monico PF, Mirza FN, Carlson KR, Foss FM, Girardi M. BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition. Oncotarget 2018, 9: 29193-29207. PMID: 30018745, PMCID: PMC6044378, DOI: 10.18632/oncotarget.25670.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaT-cell lymphomaCTCL cellsBCL2 inhibitionCell lymphomaAdvanced cutaneous T-cell lymphomaHDAC inhibitionSkin-homing T cellsPromising novel therapeutic strategyBET inhibitionNon-Hodgkin lymphomaPotential novel therapyCTCL cell linesDose-dependent decreaseNovel therapeutic strategiesHistone deacetylase inhibitionExtraterminal protein inhibitorSystemic therapyLymph nodesPeripheral bloodNovel therapiesT cellsTherapeutic strategiesCaspase-3/7 activationAdvanced stage
2017
Mycosis Fungoides and Sezary Syndrome
Foss FM, Girardi M. Mycosis Fungoides and Sezary Syndrome. Hematology/Oncology Clinics Of North America 2017, 31: 297-315. PMID: 28340880, DOI: 10.1016/j.hoc.2016.11.008.Peer-Reviewed Original ResearchConceptsSkin-directed therapiesSezary syndromeLymph nodesMycosis fungoidesAllogeneic stem cell transplantationSystemic immunomodulatory agentsVisceral organ involvementSingle-agent chemotherapyStem cell transplantationPatch/plaqueHelper T cellsExtent of skinDiffuse erythrodermaBlood involvementOrgan involvementRefractory diseaseVisceral involvementResistant diseaseRare lymphomaCell transplantationImmunomodulatory agentsPlaque diseaseCurative strategiesT cellsDisease